JOIN US FOR THE 2026 EDUCATION & SUPPORT CONFERENCE!

Dr. Kelvin A. Moses is an Assistant Professor of Urologic Surgery at Vanderbilt University Medical Center and director of the Comprehensive Prostate Cancer Clinic. His clinical practice focuses on advanced prostate cancer, including conducting several clinical trials and surgical management of advanced renal and testicular cancer. His work focuses on addressing health disparities in urologic cancers, determining the role of health literacy in patient interactions with the health care system, and optimal care for patients with metastatic and/or castrate-resistant prostate cancer. Dr. Moses also sits on ZERO’s Medical Advisory Board.

Daniel M. Geynisman, MD, is an Associate Professor in the Department of Hematology/Oncology at Fox Chase Cancer Center and the Division Chief of Genitourinary Medical Oncology, as well as the Vice Chair for Quality Improvement.

Dr. Geynisman has nearly 15 years of expertise in clinical research and medical oncology practice.

A graduate of the University of Pittsburgh School of Medicine, Dr. Geynisman completed his internal medicine residency at the University of Pittsburgh Medical Center and his fellowship in Hematology and Medical Oncology at the University of Chicago Medical Center. Board-certified in medical oncology, he specializes in the treatment of genitourinary malignancies.

His research interests focus on health outcomes evaluations in urologic malignancies, quality improvement in oncology, as well as new drug development for genitourinary malignancies. He is an active investigator on a number of past and ongoing clinical trials, with a particular focus in bladder and kidney cancer and has co-authored more than 170 manuscripts in peer-reviewed journals.

He serves on the NCCN guideline panel for testicular cancer and Wilms Tumor, is on ASCO's Ethics Committee and is the prior Medical Oncology editor for Urologic Oncology and current Editor-in-Chief of JNCCN.

Dr. Lannis Hall is Director of Radiation Oncology, Siteman Cancer Center at Barnes-Jewish St. Peters Hospital and associate professor of clinical radiation oncology at WashU Medicine. Since 2006, Dr. Hall has been a member of the Siteman Cancer Center Program to Eliminate Cancer Disparities Leadership Committee and the Leader of the Clinical Trial Outreach Core. Dr. Hall has been a member of the Disparities Elimination Advisory Committee for Washington University since 2008 and a member of the Siteman Cancer Center Senior Leadership Clinical Research Subcommittee since 2010. She is the Chair of the Cancer Oncology Conference at Barnes-Jewish St Peters and Treasurer of the Medical Executive Committee.  

She developed the clinical trials video and brochure used throughout the Siteman Cancer Center and featured on the Clinical Trials Web Page. She helped develop the Health Connections Radio Partnership with Gospel 1600 and 100.3 the Beat, delivering cancer awareness, screening/early detection, and clinical trials information for the Saint Louis Community. She is a founder of the Prostate Cancer Coalition; a group of health care providers, prostate cancer survivors, and community organizations dedicated to raising awareness about prostate cancer in high risk men. She also hosts the The Prostate Cancer Question and Answer Show, a podcast series broadcasted on Gospel 1600 and available on Spreaker, iHeart radio and iTunes. She has a special interest in prostate, breast, head and neck, and lower GI malignancies. She developed the first prostate brachytherapy program in St. Charles County in 2002 and has performed over 1100 brachytherapy procedures.

Randy Vince Jr., MD, is a native of Baltimore, Maryland. As the oldest of four siblings, he developed a passion for athletics. He attended Towson University, where he was a Varsity Letterman in Football. At Towson University, he double majored in MB3 (Molecular biology, Biochemistry, and Bioinformatics) and Chemistry. He later attended Louisiana State University Health Sciences Center in Shreveport, where he earned his MD and subsequently completed a Virginia Commonwealth University (VCU) Health Systems residency. He developed a passion for Urologic Oncology after his grandmother's passing while he was in medical school.

After residency, Dr. Vince Jr. completed a fellowship in Urologic Oncology at the University of Michigan. While at the University of Michigan, he earned a master's degree in computational medicine and bioinformatics. He has a keen interest in using precision medicine to combat the concept of racial biology and evaluate the interaction of environmental exposures and gene expression on tumor biology. Dr. Vince Jr. recently began a new position at University Hospitals and Case Western Reserve University as an assistant professor of urology and the director of minority men's health.

Marty Chakoian is a dedicated volunteer and experienced support group leader. Marty served as Board Chair of Us TOO and is now an active member of ZERO’s Board of Directors. His prostate cancer support group in Seattle meets twice each month; he is also a member of the NCI Council of Research Advocates and chairs the Pacific Northwest Prostate Cancer SPORE Patient Advocates Committee at the Fred Hutchenson Cancer Center.

Jan Manarite is the founder, CEO, and President of Your Prostate Cancer.help, which is a non-profit committed to helping patients and caregivers engage in Shared Decision Making by understanding their own cancer better, and asking better questions.  She has been a wife, caregiver, and widow - turned advocate, leading educational and advocacy efforts for over 20 years.  Learn more at www.YourPC.help. 

Alison Mayer Sachs is a distinguished leader in the field of oncology social work with decades of experience supporting cancer patients and their families. She is nationally recognized for her expertise in developing and implementing comprehensive cancer support programs that address the emotional, psychological, and practical challenges faced by those impacted by cancer. Her work has been instrumental in shaping patient-centered care models, and she has dedicated her career to fostering supportive environments that help individuals navigate their cancer journey with confidence and dignity. 

As a member of ZERO’s Medical Advisory Board, Ali brings a wealth of knowledge and compassion to her role as a moderator, ensuring that every participant in this support group feels heard, validated, and empowered. Her extensive background in counseling, patient advocacy, and program development makes her an invaluable resource for those seeking both professional guidance and community support.

Dr. Leanne Woods-Burnham is an Assistant Professor in the Department of Surgery at Morehouse School of Medicine in Atlanta, GA. Her team focuses on prostate cancer health disparities. She is a translational scientist, and her team evaluates genetic and molecular drivers of aggressive tumor biology associated with genetic ancestry. Dr. Burnham has fostered several national multidisciplinary collaborations with clinicians and pharma to conduct translational research studies and clinical trials for patients. She co-directs the Prostate Cancer Precision Prevention Program (PCP3) which leverages community partnerships to provide health education and free PSA tests to at-risk men in the greater Atlanta area. Dr. Burnham has been recognized by Cell’s #FacesofCell Twitter campaign to increase visibility of talented Black scientists, as well as The Cancer Health 25: Black Lives Matter, as a “remarkable individual breaking down racial barriers to better cancer care.” In 2025, she has been awarded “Innovator of the Year—Men’s Health” by the Atlanta Business Chronicle and “1,000 Inspiring Black Scientists in America” by Cell MENTOR.

Dr. Sokolova is an Assistant Professor of Medicine in Hematology and Medical ONcology at the Oregon Health and Science University School of Medicine. She specializes in caring for men with prostate cancer. She chose oncology because she values the special connection she has with her patients. She is honored to carry the responsibility of walking hand-in-hand with her patients during the most challenging times in their lives. She approaches each patient as a whole, addressing all aspects of their health and provide access to the best treatment that makes sense for them. Her special interests are in prostate cancer genetics. She has completed Intensive Course in Cancer Genetic Risk Assessment at City of Hope and has spent time at Memorial Sloan Kettering Genetics clinic. Her research focuses on helping men with prostate cancer and those with hereditary cancer syndromes to live well.

In her spare time, Dr. Sokolova and her husband enjoy spending time with their daughter and two cats. Dr. Sokolova also enjoys hosting family and friends, gardening and doing yoga.

Dr. Tosoian specializes in the early diagnosis and management of urologic cancers. In addition to his role as a clinician and surgeon, he is a recognized leader in clinical and translational prostate cancer research. His early research demonstrated the safety of monitoring lower-risk prostate cancers on active surveillance, allowing appropriately selected patients to delay or avoid treatment altogether. His ongoing research has led to the development of new, non-invasive tools to guide cancer diagnosis and management. Dr. Tosoian leads the Prostate Cancer Risk Clinic, a clinical program for informed early screening in patients with a strong family history or known genetic mutation associated with prostate cancer. 

Dr. Jacob Ark is a board-certified urologist with Urology of St. Louis, practicing primarily in Fairview Heights, Illinois and St. Louis, Missouri. A significant focus of his practice is the care of men with prostate cancer, with particular expertise in advanced prostate cancer, including biochemical recurrence and metastatic disease. His urologic training at Vanderbilt University Medical Center included uncommonly deep exposure to the management of Advanced Prostate Cancer. Since joining Urology of St. Louis in 2018, he has grown the largest advanced prostate cancer practice within the group. In a conscious effort to "treat the patient, not the problem," Dr. Ark's approach pairs clinical expertise with each patient's individual circumstances to tailor treatment plans and optimize outcomes.

Dr. Samuel L. Washington III is a urologic oncologist and Assistant Professor within the Departments of Urology and serve as the Associate Chair of Inclusive Excellence in the Department of Urology, the Helen Diller Family Comprehensive Cancer Center Prostate Cancer Program Community Outreach and Engagement Liaison, a member of the the NCCN Guidelines for Prostate Cancer Early Detection Panel, and as co-Director of the Community Outreach and Engagement Core for the UCSF Cancer Health Outcomes SPORE grant. He holds positions including Associate Chair of Inclusive Excellence in the Department of Urology, Helen Diller Family Comprehensive Cancer Center (HDFCCC) Prostate Cancer Program Community Outreach and Engagement Liaison, and served on the NCCN Guidelines for Prostate Cancer Early Detection Panel. His work and research, supported by the National Cancer Institute, Prostate Cancer Foundation, and The Movember Foundation, focuses on understanding how regional and healthcare system-related factors interact with race and ethnicity, geography, and social environment to perpetuate differences in urologic cancer management and how to develop mitigation strategies through interventions and organizational change.

He holds positions including Associate Chair of Inclusive Excellence in the Department of Urology, Helen Diller Family Comprehensive Cancer Center (HDFCCC) Prostate Cancer Program Community Outreach and Engagement Liaison, and served on the NCCN Guidelines for Prostate Cancer Early Detection Panel. His research portfolio includes efforts funded by National Cancer Institute, Prostate Cancer Foundation, and The Movember Foundation. His work includes co-investigator and co-principal investigator roles on projects funded by the Department of Defense and the Chan Zuckerberg Initiative with peer-reviewed publications in high-impact journals such as European Urology and JAMA Oncology.

Dr. Leeman is an Assistant Professor of Radiation Oncology at Harvard Medical School and serves as the director of MRI guided and adaptive radiotherapy at the Dana-Farber Brigham Cancer Center in Boston, MA. He received his AB from Harvard College and is a graduate of the Physician Scientist Training Program at the University of Pittsburgh School of Medicine. He completed his internship and residency in radiation oncology at Memorial Sloan Kettering Cancer Center in New York, NY where he served as Chief Resident. His clinical expertise lies in the areas of MRI guided radiotherapy, adaptive radiotherapy and prostate cancer. His research focuses on the application of MR imaging technology and adaptive radiotherapy for the advancement of prostate cancer treatment to improve treatment outcomes by reducing side effects of treatment and improving disease control for patients at all stages of disease.

Dr. Elisabeth Heath is a nationally and internationally recognized expert in genitourinary oncology, serving as the Chair of the Department of Oncology at the Mayo Clinic in Rochester, MN. She specializes in clinical and translational research, focusing on early-phase and genitourinary clinical trials and addressing important health disparities. Her expertise covers a range of genitourinary cancers, including prostate, kidney, and bladder cancer.

In addition to her clinical work, Dr. Heath has led large-scale, multi-institutional, peer-reviewed research initiatives aimed at fostering collaboration across medical disciplines. Her goal is to integrate research and clinical practice, translating scientific discoveries into real-world treatments.

Dr. Heath is also committed to improving patient access to care and their experience during treatment. She emphasizes collaboration within multidisciplinary teams to achieve holistic, effective patient outcomes. Her leadership and innovative approaches have advanced the understanding and treatment of genitourinary cancers while shaping cancer care practices both nationally and internationally. Through her work, Dr. Heath continues to contribute significantly to the oncology community, with a focus on patient-centered care and health equity.

Dr. Morgans is an Associate Professor of Medicine at Harvard Medical School, a Genitourinary Medical Oncologist and the Director of the Survivorship Program at Dana-Farber Cancer Institute. As a clinician and investigator, she has expertise in clinical trials and patient-reported outcome measures, as well as incorporating patient preferences and beliefs into clinical decision making. Her research has investigated complications of systemic therapy for prostate cancer survivors, including the study of skeletal, cardiovascular, diabetic, and cognitive complications, and her work has been funded by grants from the Prostate Cancer Foundation , the National Comprehensive Cancer Network, and the Department of Defense. She leads multiple therapeutic and quality of life focused clinical trials for prostate cancer patients, and has participated in the advanced and localized prostate cancer treatment guidelines committees of the American Urologic Association, and the cardio-oncology committee of American Heart Association.  

Rana R. McKay, MD, is a board-certified medical oncologist who specializes in treating people with urogenital cancers, including bladder, kidney, prostate and testicular cancer.

Dr. McKay leads a multi-disciplinary prostate cancer clinic. Focused on delivering advanced cancer care through a coordinated team approach, this clinic enables men diagnosed with aggressive prostate cancer - either early-stage or metastatic - to see her and a team of doctors including a urologist and radiation oncologist to provide patients with highly specialized care.

As a professor in the Department of Medicine and Department of Urology, Dr. McKay instructs medical students, residents, and fellows at UC San Diego School of Medicine. Her research interests include the design and implementation of clinical trials to including novel biomarkers and therapeutic outcomes for patients with genitourinary malignancies.

She serves as principal investigator of several early phase trials in kidney and prostate cancer. As a clinical investigator, she is committed to advancements in cancer care that will improve the lives of cancer patients.

Furthermore, she is interested in understanding mechanisms of response and resistance to specific cancer therapies. Her work has appeared in peer-reviewed publications such as Nature, Lancet, Journal of Clinical Oncology, Clinical Cancer Research, and Cancer, among others.

Before joining UC San Diego Health, Dr. McKay was a medical oncologist at the Dana-Farber/Brigham and Women's Cancer Center in Boston and an assistant professor at Harvard Medical School.

Dr. McKay completed a fellowship in oncology/hematology at the Dana-Farber Cancer Institute, Harvard Medical School. She completed a residency in internal medicine at Johns Hopkins Hospital in Baltimore, Md. Dr. McKay earned her medical degree at the University of Florida College of Medicine in Gainesville, Fla.

Dr. McKay is a member of the American Society of Clinical Oncology and the American Association for Cancer Research.

Dr. Elisabeth Heath is a nationally and internationally recognized expert in genitourinary oncology, serving as the Chair of the Department of Oncology at the Mayo Clinic in Rochester, MN. She specializes in clinical and translational research, focusing on early-phase and genitourinary clinical trials and addressing important health disparities. Her expertise covers a range of genitourinary cancers, including prostate, kidney, and bladder cancer.

In addition to her clinical work, Dr. Heath has led large-scale, multi-institutional, peer-reviewed research initiatives aimed at fostering collaboration across medical disciplines. Her goal is to integrate research and clinical practice, translating scientific discoveries into real-world treatments.

Dr. Heath is also committed to improving patient access to care and their experience during treatment. She emphasizes collaboration within multidisciplinary teams to achieve holistic, effective patient outcomes. Her leadership and innovative approaches have advanced the understanding and treatment of genitourinary cancers while shaping cancer care practices both nationally and internationally. Through her work, Dr. Heath continues to contribute significantly to the oncology community, with a focus on patient-centered care and health equity.

Leslie J. Waltke, PT, DPT is a physical therapist with a clinical mastery in cancer rehabilitation and a provider of world class cancer rehabilitation program development consulting and continuing education. Since earning her degree in Physical Therapy from the University of Wisconsin in 1988, Dr. Waltke has dedicated most of her career solely to treating the cardiopulmonary, musculoskeletal, integumentary and functional needs of persons during and after treatment for cancer. Over the past decades Dr. Waltke has cared for thousands of people with cancer and has a following of beloved patients. She is respected nationally and internationally as an oncology physical therapist, cancer rehabilitation key opinion leader,

author, educator and consultant. Since 2005 Dr. Waltke has been the Cancer Rehabilitation Coordinator for Aurora Health Care, one of

the United States’ largest CoC and NAPBC accredited cancer programs and proud holder of the rare Commission on Cancer “Outstanding Achievement Award.” Her role, in addition to treating patients with cancer, includes cancer rehabilitation program development, program integration, education and training, and best practice and clinical standards development.

A gifted and impassioned speaker, Dr. Waltke teaches and lectures throughout the world with the Waltke Cancer Rehabilitation Academy to rehab professionals, universities, medical and oncology providers, cancer organizations as well as cancer patients and survivors. She spoke at the 2014 China Cancer Congress and the 2015 and 2017 World Cancer Congresses. In 2022 she worked with the World Health Organization to standardize oncologic rehabilitation interventions. Dr. Waltke holds a certificate in Online Education from the University of Wisconsin, is a former Board Member of the Oncology Section of the American Physical Therapy Association, an APTA Credentialed Clinical Instructor, on the Specialization Academy of Content Experts and a is a founding and current board member of ABCD, Inc. (After Breast Cancer Diagnosis). Honors include the “2014 Article of the Year Award” from the Journal of Patient-Centered Research and Reviews, the 2015 Academic Excellence

and Leadership Award from Rosalind Franklin University of Medicine and Science, and the 2015 Physical Medicine and Rehabilitation Education Recognition scholarship. Dr. Waltke is a member of ASCO and ACE, the Association of Cancer Executives. Dr. Waltke’s drive and vision to make the world better for people facing illness led her to OneVillage, where she is honored to serve as Chief Wellness Officer.

Stacey A. Kenfield, ScD received her Bachelor of Science from UCLA in Physiological Science, followed by a Master of Science in Epidemiology, a Doctor of Science in Epidemiology, and a post-doctoral fellowship, all completed at the Harvard T.H. Chan School of Public Health. She continues to lead the Harvard-based Health Professionals Follow-up Study (HPFS) prostate cancer clinical follow-up of more than 7,500 men with prostate cancer since assuming this role in 2005. These data are used to identify factors that may improve prognosis and quality of life. She has worked in cancer epidemiology for the past 10 years and received a Prostate Cancer Foundation Young Investigator Award in 2012. She was recently appointed as the Helen Diller Family Chair in Population Science for Urologic Cancer in 2016.

Meredith Morgan is a board-certified acute care nurse practitioner currently working in the Urologic Oncology Clinic at the Rogel Cancer Center in Ann Arbor. She is also an adjunct faculty clinical instructor at the University of Michigan School of Nursing. She leads lectures on prostate cancer for new oncology nurses at the University of Michigan and regularly precepts nurse practitioner students. Her current practice includes prostate cancer survivorship and advanced prostate cancer. 

She is also active in prostate cancer clinical trials. She has previously worked with prostate cancer patients at Vanderbilt University Medical Center and Weill Cornell Medical College/New York-Presbyterian Hospital. Ms. Morgan has a Bachelor of Science in Psychology from the University of Georgia and a Master of Science in Nursing from Vanderbilt University. She is a member of the American Urological Association, Oncology Nursing Society, Society of Urologic Nurses and Associates, and the Michigan Council of Nurse Practitioners.

Alison Mayer Sachs is a distinguished leader in the field of oncology social work with decades of experience supporting cancer patients and their families. She is nationally recognized for her expertise in developing and implementing comprehensive cancer support programs that address the emotional, psychological, and practical challenges faced by those impacted by cancer. Her work has been instrumental in shaping patient-centered care models, and she has dedicated her career to fostering supportive environments that help individuals navigate their cancer journey with confidence and dignity. 

As a member of ZERO’s Medical Advisory Board, Ali brings a wealth of knowledge and compassion to her role as a moderator, ensuring that every participant in this support group feels heard, validated, and empowered. Her extensive background in counseling, patient advocacy, and program development makes her an invaluable resource for those seeking both professional guidance and community support.

Meredith Morgan is a board-certified acute care nurse practitioner currently working in the Urologic Oncology Clinic at the Rogel Cancer Center in Ann Arbor. She is also an adjunct faculty clinical instructor at the University of Michigan School of Nursing. She leads lectures on prostate cancer for new oncology nurses at the University of Michigan and regularly precepts nurse practitioner students. Her current practice includes prostate cancer survivorship and advanced prostate cancer. 

She is also active in prostate cancer clinical trials. She has previously worked with prostate cancer patients at Vanderbilt University Medical Center and Weill Cornell Medical College/New York-Presbyterian Hospital. Ms. Morgan has a Bachelor of Science in Psychology from the University of Georgia and a Master of Science in Nursing from Vanderbilt University. She is a member of the American Urological Association, Oncology Nursing Society, Society of Urologic Nurses and Associates, and the Michigan Council of Nurse Practitioners.

Dr. Abhinav Khanna is a Urologic Oncologist and Robotic Surgeon at Mayo Clinic. Dr. Khanna graduated with Alpha Omega Alpha Honors from Baylor College of Medicine. He completed Urology Residency at Cleveland Clinic, one of the top-ranked urology residency programs in the nation. Dr. Khanna completed specialized fellowship training in Urologic Oncology at Mayo Clinic. As a Urologic Oncologist, he specializes in prostate cancer, kidney cancer, and bladder cancer. Dr. Khanna has expertise in robotic surgery for urologic cancer, including nerve-sparing robotic prostatectomy, complex robotic partial nephrectomy, and fully robotic radical cystectomy with intracorporeal urinary diversion. His research focuses on developing and implementing artificial intelligence tools to enhance the diagnosis and treatment of urologic cancers. He serves as the Medical Director of the inpatient urology practice at Mayo Clinic Rochester Methodist Hospital, and is also the Fellowship Director of the Grainger Research Fellowship in Urology. His practice philosophy focuses on providing compassionate and empathetic care to each individual patient, and he has been recognized as one of the top performing physicians at Mayo Clinic for Patient Experience.

Hi, my name is Sam Jolley, PA‑C, and I work with Minnesota Urology in men’s health, with a particular focus on prostate cancer recovery. I’m originally from South Dakota and earned my Master’s degree in Physician Assistant Studies from the University of South Dakota in 2019. I moved to Minneapolis in July of 2025. In my practice, I work closely with patients after prostate cancer surgery and radiation treatment, helping them through recovery—particularly managing erectile dysfunction and stress urinary incontinence following prostatectomy.

The Rev. Leroy Miles combines faith leadership with public health advocacy. As Associate Pastor for Pastoral Care and Counseling at Enon Tabernacle Baptist Church in Philadelphia, he has developed ministries addressing mental health, HIV/AIDS, and addiction, and recently launched a doula program to address Black maternal health disparities.

He serves on the board of Nephcure, supporting research and awareness for rare kidney disease, and is a consultant specializing in community engagement strategies. A certified anger management educator and graduate of the FBI Citizens Academy, his commitment to service also includes a chaplaincy internship at Children's Hospital of Philadelphia (CHOP) and leading COVID-19 testing and vaccination efforts.

Rev. Miles is also an avid cyclist, martial arts black belt, and endurance event competitor.

Dr. Imholte received a Ph.D. in clinical human sexuality (2017) and a master's in human sexuality education (2010) from Widener University. Prior to attending Widener University, Shelley graduated with a master's degree in clinical social work (2007) from the University of Texas at Austin. For over a decade, Dr. Imholte has offered specialized sexuality whole-person psychotherapy services as the owner and operator of Sexual Life Improvement, Inc., located in Austin, Texas. Shelley is proud to be a volunteer support professional with UsToo for years and anticipates continuing her professional support for Zero, More information about Dr. Imholte can be found at www.sexuallifeimprovement.com .

Yadira Montoya’s work focuses on advancing health equity and racial justice. She has over fifteen years of experience across multiple sectors, including academia, non-profit, and philanthropy. In 2019, she was recognized as a Culture of Health Leader by the Robert Wood Johnson Foundation for her leadership in community efforts that improve aging equity and the health and wellbeing of Latinx dementia family caregivers.

Prior to joining the National Alliance for Caregiving, Yadira served as a Program Officer at the Lloyd A. Fry Foundation. In this role, she oversaw the Foundation’s health portfolio and worked to increase access to primary care and reducing health care disparities for Chicago’s low-income residents. Prior to Fry, Yadira was a Research Scientist at NORC at the University of Chicago where she led and supported a broad range of research studies focused aging, public health, and participatory methods for clients in the nonprofit, government, and philanthropic sectors.

Yadira plays a leadership role in many Chicago-based aging and caregiving organization. She is a founding member of La BROCHA an innovative community arts program for Latinx older adults, especially individuals with dementia and Parkinson’s disease, living in disinvested communities. She currently sits on several boards and committees, including the Alzheimer’s Coalition for Advocacy, Research, and Education and Solutions for Care.

Yadira earned her Bachelor’s in Community Health and Master of Science in Public Health from the University of Illinois at Urbana-Champaign.